Schrödinger, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the quarterly period ended September 30, 2026.
Key Highlights
- Share count: As of October 28, 2026, the company had 65,913,601 shares of common stock and 9,164,193 shares of limited common stock outstanding, each with a par value of $0.01 per share.
- Large accelerated filer: Schrödinger, Inc. is classified as a large accelerated filer under the Exchange Act definitions.
- Exchange listing: Common stock trades on The Nasdaq Stock Market LLC under the ticker NASDAQ:SDGR.
- Agentic AI platform: The filing references Bunsen, described as the company's agentic artificial intelligence co-scientist, with an anticipated full commercial release noted among forward-looking statements.
- Collaboration disclosed: Forward-looking statements in the filing include references to a collaboration agreement with Novartis Pharma AG, including potential milestone and other payments.
- Not a shell company: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
Schrödinger's September 30, 2026 Quarterly Filing: Structure and Key Disclosures
Schrödinger, Inc. (NASDAQ:SDGR), a computational drug discovery and software company headquartered at 1540 Broadway, 24th Floor, New York, NY 10036, submitted its quarterly report on Form 10-Q for the period ended September 30, 2026. The filing carries Commission File Number 001-39206 and was made under the Securities Exchange Act of 1934. The registrant confirmed it had filed all required reports during the preceding 12 months and had submitted all required Interactive Data Files electronically.
According to the filing, as of October 28, 2026, Schrödinger had 65,913,601 shares of common stock and 9,164,193 shares of limited common stock outstanding, both carrying a par value of $0.01 per share. The company is incorporated in Delaware and holds an IRS Employer Identification Number of 95-4284541.
The filing contains a cautionary note regarding forward-looking statements, which the company states involve "substantial risks and uncertainties." Among the topics covered by those forward-looking statements, as identified by the registrant, are the anticipated capabilities and commercial release of Bunsen, the company's agentic artificial intelligence co-scientist, plans to accelerate software business growth, drug discovery collaboration progress including under an agreement with Novartis Pharma AG, and expectations related to operating expenses following a restructuring of operations. The company expressly cautions that actual results may differ materially from those disclosed in forward-looking statements and that it does not assume any obligation to update them except as required by applicable law.
What Was Disclosed
Schrödinger filed its quarterly report for the period ended September 30, 2026, disclosing share counts as of October 28, 2026, its large accelerated filer status, and forward-looking statements covering software growth, drug discovery collaborations, and an agentic AI platform.




Please wait processing your request...